Researchers at the London School of Economics and Political Science (LSE) conducted cost-effectiveness analyses for both the CST and maintenance CST trials (11,12). Both found that CST is more cost-effective than usual care when looking at benefits in cognition and quality of life.
The NHS conducted an economic evaluation of the alternatives to antipsychotic drugs for individuals living with dementia (13). Their analysis focused on the cost of providing CST. They found that, combining health care cost savings and quality of life improvements; CST could generate a net benefit of nearly £54.9 million per year for the NHS.